3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
5
Phase 3
2
Phase 1/2
2
Phase 4
1
Status
Terminated
3
Recruiting
3
Active not recruiting
2
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Breast Neoplasms
108
Carcinoma, Non-Small-Cell Lung
95
Prostatic Neoplasms
58
Multiple Myeloma
45
Neoplasms
38
Neoplasm Metastasis
33
Ovarian Neoplasms
26
Melanoma
24
Urinary Bladder Neoplasms
23
Lung Neoplasms
22
Colorectal Neoplasms
22
Recurrence
21
Leukemia, Lymphocytic, Chronic, B-Cell
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
20
Carcinoma, Renal Cell
20
Carcinoma, Hepatocellular
17
Triple Negative Breast Neoplasms
16
Nasopharyngeal Carcinoma
16
Lymphoma, Non-Hodgkin
16
Stomach Neoplasms
15
Leukemia, Myeloid, Acute
15
Lymphoma
14
Squamous Cell Carcinoma of Head and Neck
13
Small Cell Lung Carcinoma
13
Fallopian Tube Neoplasms
12
Colonic Neoplasms
12
Carcinoma
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, Follicular
11
Interventions
venetoclax
2
obinutuzumab
2
ibrutinib
1
acalabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Active not recruiting
×
Leukemia, B-Cell
×
Clear all
NCT04608318
2026-04-30
CLL17
German CLL Study Group
Phase 3
Active not recruiting
897 enrolled
NCT03836261
2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3
Active not recruiting
984 enrolled
1 FDA